Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.

Treatment of SV40-infected monkey cells with amonafide (benzisoquinolinedione), an intercalative antitumor drug, resulted in rapid accumulation of linearized intracellular SV40 DNA molecules that were protein linked. Studies using purified mammalian DNA topoisomerase II have shown that amonafide and its structural analogs interfere with the breakage-rejoining reaction of the enzyme by stabilizing a reversible enzyme-DNA "cleavable complex." Denaturation of the cleavable complex with sodium dodecyl sulfate resulted in DNA cleavage and the covalent association of topoisomerase II polypeptides with the cleaved DNA. Unwinding measurements indicate that amonafide is a DNA intercalator. These results suggest that amonafide and its structural analogs (e.g., mitonafide) represent a new class of intercalative topoisomerase II-active antitumor drugs. Different from other topoisomerase II-active antitumor drugs, amonafide and mitonafide induce specific DNA cleavage at a single major site on pBR322 DNA. The strong site specificity of amonafide may allow detailed characterization of the intercalator-stabilized, topoisomerase II-DNA cleavable complex.

• Publication year

  1989

• Venue

  Molecular Pharmacology

• Publication date

  1989-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/s0026-895x(25)09304-6PMID 2550774
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1,8 naphthalic acid

  2004cited by this paper
• Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons.

  1989cited by this paper
• DNA topoisomerase poisons as antitumor drugs.

  1989cited by this paper
• Topoisomerases: novel therapeutic targets in cancer chemotherapy.

  1988cited by this paper
• DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy.

  1987cited by this paper
• In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia.

  1987cited by this paper
• DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II.

  1986cited by this paper
• Purification and characterization of a type II DNA topoisomerase from bovine calf thymus.

  1985cited by this paper
• Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship.

  1984cited by this paper
• Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.

  1984cited by this paper
• Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.

  1984cited by this paper
• Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.

  1984cited by this paper
• Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.

  1984cited by this paper
• Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.

  1984cited by this paper
• Cleavage of DNA by mammalian DNA topoisomerase II.

  1983cited by this paper
• Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei.

  1981cited by this paper
• Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin.

  1981cited by this paper
• Qualitative and quantitative aspects of intercalator-induced DNA strand breaks.

  1979cited by this paper
• Intercalative binding to DNA of antitumour drugs derived from 3-nitro- 1, 8-naphthalic acid

  1979cited by this paper
• Protein-associated DNA breaks in cells treated with adriamycin or ellipticine.

  1978cited by this paper

• Topoisomerase inhibitor amonafide enhances defense responses to promote longevity in C. elegans

  2025cites this paper
• New Succinimides with Potent Anticancer Activity: Synthesis, Activation of Stress Signaling Pathways and Characterization of Apoptosis in Leukemia and Cervical Cancer Cells

  2021cites this paper
• Naphthalimide-based macrophage nucleus imaging probes.

  2020cites this paper
• Síntesis de inhibidores de Atg4B y desarrollo de nuevos métodos de bioconjugación basados en derivados del ácido escuárico

  2019cites this paper
• Identification of benzo[cd]indol-2(1H)-ones as novel Atg4B inhibitors via a structure-based virtual screening and a novel AlphaScreen assay.

  2019cites this paper
• Synthesis, Characterization, Quantum-Chemical Calculations and Cytotoxic Activity of 1,8-Naphthalimide Derivatives with non-Protein Amino Acids.

  2019cites this paper
• Synthesis of a 3,4-Disubstituted 1,8-Naphthalimide-Based DNA Intercalator for Direct Imaging of Legionella pneumophila

  2019cites this paper
• The development and validation of an LC-MS/MS method for the quantification of CZ112, a prodrug of 9-Nitrocamptothecin in rat plasma.

  2019cites this paper
• Reliable Target Prediction of Bioactive Molecules Based on Chemical Similarity Without Employing Statistical Methods

  2019cites this paper
• Caspase-independence and characterization of bisnaphthalimidopropyl spermidine induced cytotoxicity in HL60 cells.

  2018cites this paper
• Synthesis and biological activity of fused tetracyclic Pyrrolo[2,1-c][1,4]benzodiazepines

  2018cites this paper
• Anticancer Activity and Topoisomerase II Inhibition of Naphthalimides with ω-Hydroxylalkylamine Side-Chains of Different Lengths.

  2018cites this paper
• A novel triazolonaphthalimide induces apoptosis and inhibits tumor growth by targeting DNA and DNA-associated processes

  2017cites this paper
• Naphthalimides Selectively Inhibit the Activity of Bacterial, Replicative DNA Ligases and Display Bactericidal Effects against Tubercle Bacilli

  2017cites this paper
• An in vitro investigation of the antitumour efficacy of novel hybrids containing artemisinin, porphyrin, or naphthalimide derivatives /

  2017cites this paper
• Discovery of potent molecular chimera (CM358) to treat human metastatic melanoma.

  2017cites this paper
• Inhibitors and Poisons of Mammalian Type II Topoisomerases

  2017cites this paper
• New, Substituted Derivatives of Dicarboximides and their Cytotoxic Properties.

  2016cites this paper
• Effect of intercalator substituent and nucleotide sequence on the stability of DNA- and RNA-naphthalimide complexes.

  2015cites this paper
• Characterisation of cyto- and genotoxicity of novel bisnaphthalpolyamines within pancreatic cancer cells

  2014cites this paper
• Novel DNA Topoisomerase IIα Inhibitors from Combined Ligand- and Structure-Based Virtual Screening

  2014cites this paper
• Synthesis and study of antiproliferative, antitopoisomerase II, DNA-intercalating and DNA-damaging activities of arylnaphthalimides.

  2013cites this paper
• Topoisomerase inhibitors as anticancer agents: a patent update

  2013cites this paper
• Recent advances in the development of 1,8-naphthalimide based DNA targeting binders, anticancer and fluorescent cellular imaging agents.

  2013cites this paper
• Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?

  2012cites this paper
• The influence of bisnaphthalimidopropyl polyamines on DNA instability and repair in Caco-2 colon epithelial cells

  2011cites this paper
• Derivatives of 5-nitro-1H-benzo[de]isoquinoline-1,3(2H)-dione: design, synthesis, and biological activity

  2010cites this paper
• Novel naphthalimide-amino acid conjugates with flexible leucine moiety as side chain: design, synthesis and potential antitumor activity.

  2009cites this paper
• Synthesis, cytotoxic evaluation and in silico pharmacokinetic prediction of some benzo[a]phenazine-5-sulfonic acid derivatives.

  2009cites this paper
• Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma

  2009cites this paper
• Naphthalimides and azonafides as promising anti-cancer agents.

  2009cites this paper
• Overview of naphthalimide analogs as anticancer agents.

  2009cites this paper
• M(2)-A induces apoptosis and G(2)-M arrest via inhibiting PI3K/Akt pathway in HL60 cells.

  2009cites this paper
• Towards sequence selective DNA binding: design, synthesis and DNA binding studies of novel bis-porphyrin peptidic nanostructures.

  2008cites this paper
• Genotoxicity of topoisomerase II inhibitors: an anti-infective perspective.

  2008cites this paper
• Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux.

  2008cites this paper
• Synthesis and anticancer activities of 6-amino amonafide derivatives

  2008cites this paper
• 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity.

  2007cites this paper
• Tri-, tetra- and heptacyclic perylene analogues as new potential antineoplastic agents based on DNA telomerase inhibition.

  2007cites this paper
• R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II

  2007cites this paper
• Comparative analysis of xanafide cytotoxicity in breast cancer cell lines

  2007cites this paper
• Rational Design and Molecular Effects of a New Topoisomerase II Inhibitor , Azatoxin 1

  2006cites this paper
• Anticancer drug discovery and pharmaceutical chemistry: a history

  2006cites this paper
• Amrubicin induces apoptosis in human tumor cells mediated by the activation of caspase‐3/7 preceding a loss of mitochondrial membrane potential

  2006cites this paper
• Patterns of post-translational histone modifications, chromatin condensation and DNA fragmentation during apoptosis

  2006cites this paper
• Intercalating nucleic acids containing insertions of naphthalimide

  2006cites this paper
• Etoposide and 4 Cleavage / Religation and Sensitivity to the Antineoplastic Drugs Protein Kinase C : Effects on Enzyme-mediated DNA Phosphorylation of Topoisomerase II by Casein Kinase II and Updated Version

  2006cites this paper
• Novel DNA bis-intercalators of isoquinolino[4,5-bc]acridines: design, synthesis and evaluation of cytotoxic activity

  2005cites this paper
• Phase II study of amonafide in patients with recurrent glioma

  2005cites this paper
• Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide.

  2005cites this paper
• Synthesis, biological activity, and quantitative structure-activity relationship study of azanaphthalimide and arylnaphthalimide derivatives.

  2004cites this paper
• Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography

  2004cites this paper
• Phase I study of mitonafide with a 3-day administration schedule: Early interruption due to severe central nervous system toxicity

  2004cites this paper
• Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono- and bisfuronaphthalimides.

  2003cites this paper
• DNA Topoisomerases in Cancer Therapy

  2003cites this paper
• Development of new topoisomerase II-targeting compounds as candidate anticancer drugs

  2003cites this paper
• Quinolones and Eukaryotic Topoisomerases

  2003cites this paper
• Phase I a nd P harmacokinetic S tudy o f L U79553, a D NA Intercalating B isnaphthalimide , i n P atients W ith S olid Malignancies

  2001cites this paper
• Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.

  2001cites this paper
• Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.

  1999cites this paper
• The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.

  1998cites this paper
• Analysis of a Core Domain in Drosophila DNA Topoisomerase II

  1998cites this paper
• Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.

  1998cites this paper
• Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents

  1997cites this paper
• DNA topoisomerase targeting drugs: mechanisms of action and perspectives.

  1997cites this paper
• DNA Topoisomerase II Inhibitors

  1997cites this paper
• Fluorescence of Chromatin DNA Induced by Antitumoral Naphthalimides

  1997cites this paper
• Molecular modeling of intercalation complexes of antitumor active 9-aminoacridine and a [d, e]-anellated isoquinoline derivative with base paired deoxytetranucleotides

  1996cites this paper
• Clinical pharmacokinetics of amonafide (NSC 308847) in 62 patients.

  1996cites this paper
• Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.

  1996cites this paper
• Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi

  1996cites this paper
• Topoisomerase II as a target for anticancer chemotherapy.

  1995cites this paper
• Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.

  1995cites this paper
• Synthesis, structure and antitumor activity of new benz[d,e]isoquinoline-1,3-diones.

  1995cites this paper
• Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage.

  1995cites this paper
• Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.

  1995cites this paper
• Topoisomerases in Multidrug Resistance

  1995cites this paper
• Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).

  1995cites this paper
• Preclinical evaluation of LU 79553: a novel bis-naphthalimide with potent antitumor activity.

  1995cites this paper
• Phase II evaluation of amonafide in advanced sarcoma: a Southwest Oncology Group study.

  1994cites this paper
• Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors

  1994cites this paper
• Clinical development of topoisomerase-interactive drugs.

  1994cites this paper
• Antiestrogenic piperidinediones designed prospectively using computer graphics and energy calculations of DNA-ligand complexes.

  1994cites this paper
• Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors.

  1994cites this paper
• Mechanism of action of topoisomerase II-targeted antineoplastic drugs.

  1994cites this paper
• Bootstrap validation of pharmacodynamic models defined via stepwise linear regression

  1994cites this paper
• When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs.

  1993cites this paper
• Phase I study of amonafide dosing based on acetylator phenotype.

  1993cites this paper
• XB596, a promising bis‐naphthalimide anti‐cancer agent

  1993cites this paper
• Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis: evidence for a common mechanism of regulation by phosphorylation.

  1993cites this paper
• DNA topoisomerase I and II as targets for rational design of new anticancer drugs.

  1993cites this paper
• A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential

  1993cites this paper
• Woodfruticosin (woodfordin C), a new inhibitor of DNA topoisomerase II. Experimental antitumor activity.

  1992cites this paper
• Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.

  1992cites this paper
• Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events.

  1992cites this paper
• Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin.

  1992cites this paper
• Effect of casein kinase II-mediated phosphorylation on the catalytic cycle of topoisomerase II. Regulation of enzyme activity by enhancement of ATP hydrolysis.

  1992cites this paper
• Woodfruticosin (woodfordin C), a new inhibitor of DNA topoisomerase II: Experimental antitumor activity

  1992cites this paper
• DNA topoisomerase-targeting antitumor agents and drug resistance.

  1992cites this paper
• Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.

  1992cites this paper